Eighty-five percent of DSH hospitals earned more in estimated 340B revenue in 2022 than they incurred in charity care costs, [...] …
Articles by : Rich Daly, Editor in Chief
Federal auditors determined terminations from the 340B program were required for either a covered entity site or a contract pharmacy [...] …
A federal judge recently dismissed a large California health system’s whistleblower case against four pharmaceutical companies for alleged fraudulent 340B [...] …
While it appears that Senate and House appropriators have agreed on a funding level for the office that oversees the [...] …
A California ballot initiative aims to codify the California governor’s 2019 shift of the Medicaid program’s prescription drug benefit from [...] …
Although 340B participation did not correlate to the start of costly treatment for men with advanced prostate cancer enrolled in [...] …
Despite the increase in the amount of 340B program drug discounts, those only amounted to 3.1% of global and 7% [...] …
A University of California at Berkeley academic is proposing a series of major reforms to the 340B discount drug program [...] …
Long-awaited federal legislation to bar drugmaker restrictions on 340B contract pharmacy arrangements was introduced today. The Mar 12 bill sponsored [...] …
Drugmaker Genentech has given some 340B hospitals advance notice of its plan to implement contract pharmacy restrictions. The biotech giant, [...] …